Cargando…

Testosterone and the Heart

The development of a subnormal level of testosterone (T) is not universal in ageing men, with 75% of men retaining normal levels. However, a substantial number of men do develop T deficiency (TD), with many of them carrying a portfolio of cardiovascular (CV) risk factors, including type 2 diabetes (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirby, Michael, Hackett, Geoffrey, Ramachandran, Sudarshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659039/
https://www.ncbi.nlm.nih.gov/pubmed/31360231
http://dx.doi.org/10.15420/ecr.2019.13.1
_version_ 1783439056987750400
author Kirby, Michael
Hackett, Geoffrey
Ramachandran, Sudarshan
author_facet Kirby, Michael
Hackett, Geoffrey
Ramachandran, Sudarshan
author_sort Kirby, Michael
collection PubMed
description The development of a subnormal level of testosterone (T) is not universal in ageing men, with 75% of men retaining normal levels. However, a substantial number of men do develop T deficiency (TD), with many of them carrying a portfolio of cardiovascular (CV) risk factors, including type 2 diabetes (T2D) and the metabolic syndrome. TD increases the risk of CV disease (CVD) and the risk of developing T2D and the metabolic syndrome. The key symptoms suggesting low T are sexual in nature, including erectile dysfunction (ED), loss of night-time erections and reduced libido. Many men with heart disease, if asked, admit to ED being present; a problem that is often compounded by drugs used to treat CVD. A large number of studies and meta-analyses have provided evidence of the link between TD and an increase in CVD and total mortality. Patients with chronic heart failure (CHF) who have TD have a poor prognosis and this is associated with more frequent admissions and increased mortality compared with those who do not have TD. Conversely, in men with symptoms and documented TD, T therapy has been shown to have beneficial effects, namely improvement in exercise capacity in patients with CHF, improvement of myocardial ischaemia and coronary artery disease. Reductions in BMI and waist circumference, and improvements in glycaemic control and lipid profiles, are observed in T-deficient men receiving T therapy. These effects might be expected to translate into benefits and there are more than 100 studies showing CV benefit or improved CV risk factors with T therapy. There are flawed retrospective and prescribing data studies that have suggested increased mortality in treated men, which has led to regulatory warnings, and one placebo-controlled study demonstrating an increase in coronary artery non-calcified and total plaque volumes in men treated with T, which is open for debate. Men with ED and TD who fail to respond to phosphodiesterase type 5 (PDE5) inhibitors can be salvaged by treating the TD. There are data to suggest that T and PDE5 inhibitors may act synergistically to reduce CV risk.
format Online
Article
Text
id pubmed-6659039
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-66590392019-07-29 Testosterone and the Heart Kirby, Michael Hackett, Geoffrey Ramachandran, Sudarshan Eur Cardiol Ischaemic Heart Disease, Stroke and Risk Factors The development of a subnormal level of testosterone (T) is not universal in ageing men, with 75% of men retaining normal levels. However, a substantial number of men do develop T deficiency (TD), with many of them carrying a portfolio of cardiovascular (CV) risk factors, including type 2 diabetes (T2D) and the metabolic syndrome. TD increases the risk of CV disease (CVD) and the risk of developing T2D and the metabolic syndrome. The key symptoms suggesting low T are sexual in nature, including erectile dysfunction (ED), loss of night-time erections and reduced libido. Many men with heart disease, if asked, admit to ED being present; a problem that is often compounded by drugs used to treat CVD. A large number of studies and meta-analyses have provided evidence of the link between TD and an increase in CVD and total mortality. Patients with chronic heart failure (CHF) who have TD have a poor prognosis and this is associated with more frequent admissions and increased mortality compared with those who do not have TD. Conversely, in men with symptoms and documented TD, T therapy has been shown to have beneficial effects, namely improvement in exercise capacity in patients with CHF, improvement of myocardial ischaemia and coronary artery disease. Reductions in BMI and waist circumference, and improvements in glycaemic control and lipid profiles, are observed in T-deficient men receiving T therapy. These effects might be expected to translate into benefits and there are more than 100 studies showing CV benefit or improved CV risk factors with T therapy. There are flawed retrospective and prescribing data studies that have suggested increased mortality in treated men, which has led to regulatory warnings, and one placebo-controlled study demonstrating an increase in coronary artery non-calcified and total plaque volumes in men treated with T, which is open for debate. Men with ED and TD who fail to respond to phosphodiesterase type 5 (PDE5) inhibitors can be salvaged by treating the TD. There are data to suggest that T and PDE5 inhibitors may act synergistically to reduce CV risk. Radcliffe Cardiology 2019-07-11 /pmc/articles/PMC6659039/ /pubmed/31360231 http://dx.doi.org/10.15420/ecr.2019.13.1 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Ischaemic Heart Disease, Stroke and Risk Factors
Kirby, Michael
Hackett, Geoffrey
Ramachandran, Sudarshan
Testosterone and the Heart
title Testosterone and the Heart
title_full Testosterone and the Heart
title_fullStr Testosterone and the Heart
title_full_unstemmed Testosterone and the Heart
title_short Testosterone and the Heart
title_sort testosterone and the heart
topic Ischaemic Heart Disease, Stroke and Risk Factors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659039/
https://www.ncbi.nlm.nih.gov/pubmed/31360231
http://dx.doi.org/10.15420/ecr.2019.13.1
work_keys_str_mv AT kirbymichael testosteroneandtheheart
AT hackettgeoffrey testosteroneandtheheart
AT ramachandransudarshan testosteroneandtheheart